ERBB2 and neoplasm: Treatment of HEK293 cells with sorafenib substantially inhibited MAPK pathway signaling and promoted some degradation of eYFP-CRAF over 24 hr, although to a much smaller degree than in our previous observations for (1) vemurafenib and BRAFV600E, (2) lapatinib and ErbB2, and (3) erlotinib and EGFRG719S (Polier et al., 2013) in tumor cells (Figure S2A).